I wanted to remind you to check out my upcoming Business Development course offered by UC Berkeley Extension on Thursday and Friday, June 19-20 in downtown San Francisco. See the details for this unique course that is focused on learnings for life science industry professionals working in or in support of licensing, partnering, and alliance management below:
Course: “Life Science Business Development,” (formerly known as Biotechnology Business Development)
Dates and Time: Thursday and Friday, June 19-20; 8:30 am – 5:00 pm for classroom intensive and balance of term for working on term projectLocation: Downtown University of California, Berkeley Extension, 425 Market St., 8th Floor, San Francisco, CA 94105
Cost: Summer term—fee: $895, (440.8-001). Registration is open at http://tinyurl.com/mao7hjh
This intensive course including two days of classroom and balance of term for individual research is designed to provide participants with an understanding of the critical role business development and licensing functions play in the commercialization of new products or technology and to the development of a successful life science company. The term assignment is designed to give students the opportunity to put the knowledge and materials from class to immediate and practical use with resulting document for inclusion in their portfolio.
Upon successful completion of the course, participants will:
- Understand the various aspects of the business development function in the life science industry and appreciate the skills required to be effective in business development and licensing roles
- Appreciate types of deals and their role in commercialization strategies and funding of a company
- Understand importance of IP status and patent life cycle planning
- Appreciate the role of pricing and reimbursement in the commercial assessment of life science innovations that underlie deal valuations
Who Will Benefit from This Course
This course is suitable for marketing and business development professionals as well as scientific professionals working in bioscience companies, especially those considering a career move into BD. Licensing, potential entrepreneurs, scientific, clinical, regulatory financial, legal and auxiliary personnel will also benefit from insights gained in the course. Although there are no format prerequisites, those who have been exposed to the life science industry and/or the Drug Development Process course will most benefit from the course.
Lectures, discussion, and guest expert lecturers will address business development topics and issues. Student will be exposed to templates and primers for major business development documents and offered mentoring by instructor in researching and developing their term project. They will have access to two major industry databases for use in researching their project during the term. These include Deloitte’s Basic Recap.com, a life science deal database, and BioCentury’s Report on BioBusiness and access to latter’sarchives.
An extensive hard-copy reader, including lecture slides for note-taking, templates for frequently-used business development documents and a sizable online accessible reference list, will be prepared and distributed by the instructor for use by students during and after class.
Audrey Erbes, Ph.D., Principal, Erbes & Associates and http://www.audreysnetwork.com, is a life-science business development and marketing consultant and developer of customized executive education. With more than 30 years of managerial experience in the biotech and pharmaceutical industry, she was Executive Vice President and cofounder of Kowa Research Institute, a biopharmaceutical licensing and investment subsidiary of Kowa Company Ltd., Japan and before that held U.S. and global management positions at Syntex Corp. (acquired by Roche) in market research, product management, strategic marketing and planning, and business development.
Guest Speakers and Their Topics
Jessica L. Holmes,Director of Reimbursement for Argenta Advisors, has 20 years of experience in payer relations, government affairs, reimbursement strategy and tactical planning. She has worked for manufacturers in home infusion therapy, medical device, biotechnology, capital equipment and diagnostics. Jessica provides expertise in analyzing challenges and opportunities for market access in not only the traditional reimbursement environment of Medicare and commercial health plans, but in the evolving landscape of risk-sharing/gain-sharing programs (e.g., ACOs) and pay-for-performance initiatives. Jessica uses her Degree in Mass Communications from UC Berkeley and her work in public relations to cross-functionally align reimbursement goals with corporate sales/marketing initiatives. Topic: “Developing and Positioning Technology in the Evolving Healthcare Reimbursement Landscape”
Harold (Hal) Etterman, MBA,CEO, Knight Financial Plans & Services, LLC has over twenty-five years experience in Finance, Operations and Information Technology, including over ten years serving as a CFO, COO and interim CEO. Hal’s extensive international and domestic experience includes medial devices, software development, medical information publishing, Internet/data security and Homeland security systems. Hal had earlier worked for Siemens Medical Systems for nearly 17 years in Manufacturing Operations, Divisional Sales and Service, Corporate Finance and Information Systems. After Siemens, Hal was the CFO/COO for a medical laser manufacturer and has served as a financial planning consultant for 3 medical device businesses. Most recently he has just completed four major Sarbanes-Oxley projects where he successfully helped his client firms through their internal audits resulting in SOX certified SEC filings. Topic: “Financial Planning and Funding for a Bioscience Venture: New, Emerging and Growing Entities”
Carolyn Feamster, MBA, a business strategy and analysis consultant, has over 25 years experience in the pharmaceutical and biotech therapeutics, diagnostics and drug delivery systems. She has broad expertise across numerous therapeutic areas, including oncology, CNS, transplantation, autoimmune disease, women’s health and urology. Carolyn worked in R&D and pharmaceutical marketing at Syntex, where her responsibilities included the major brands Naprosyn and Cellcept. In 1995, Carolyn joined ALZA Corporation as Senior Director of New Product Marketing with commercial responsibility for building and managing the pipeline products. She shepherded three products onto the market and was instrumental in evolving the three ALZA therapeutic franchises: urology, CNS and oncology. Carolyn was VP of New Product Planning at Corixa Corporation and, most recently, Vice President of Business Strategy and Analysis at Clearview Projects. Topic: “Preparing for and Planning Deals for Maximum Strategic Impact”
Gilbert R. Mintz, Ph.D., President of GRM Associates, a biotechnology business development, licensing, strategic planning consulting firm, has expertise in building early-stage companies by focusing their strategic planning and licensing activities, and raising money through venture capitalists. His 20-plus years in the biotechnology industry include general and laboratory management and executive level business development roles. He has executed technology platform, corporate and academic collaborations; in/out licensing of late-stage products for partnerships in the US, Europe and Japan; as well as analyzed and managed intellectual property activities. He has consulted with Affymetrix and other biotechnology companies; served as the President and CEO, Director of an early-stage cancer company; and provided transactional and strategic planning advice to numerous pre-IPO biotechnology companies. He has held senior management positions at Genelabs Technologies, Anergen (Corixa), Cygnus and Trega Biosciences. Topic: “Working Your Way through the Bioscience Licensing Process: Negotiating and Writing Deal Contract”
Ginger Dreger, J.D., M.S., partner in Arnold & Porter LLP’s intellectual property practice group, concentrates her practice on counseling and providing strategic advice to emerging and established public companies in the biotechnology, medical device, and pharmaceutical industries. She advises clients on domestic and international patent matters, including worldwide patent protection and enforcement strategies; freedom-to-operate issues; intellectual property due diligence; and analysis of third-party patents. Corporate experience included role with Genentech’s in-house legal department. Topic: “What You Need to Know about Patents Working in Business Development”
Chris Dokomajilar serves as the Director of Business Intelligence at BioCentury where he is responsible for growth initiatives across biopharmaceutical deals and business information. Chris was previously at Recap at Thomson Reuters (formerly Deloitte Recap LLC and Recombinant Capital) as the Senior Deal Analyst managing a data and consulting group covering biopharmaceutical licensing, M&A, and financing. He enjoys the opportunity to contribute to industry thought-leadership and is frequently invited to speak to trade and industry groups about business development, licensing, and commercialization.
Prior to joining Recap, Chris managed international labs and clinical research at the University of California San Francisco. His research on epidemiological trends in infectious diseases has been published in medical and scientific journals. Before transitioning into science, Chris served in finance positions of increasing responsibility at Bank of America. He holds bachelor’s degrees from the University of California Berkeley in Molecular and Cell Biology and in Integrative Biology. Topic: “BioPharma Alliances: Trends in the Marketplace”
Course Content Outline
- The Function of Business Development In A Bioscience Company
- Financing The Development And Commercialization Process Of Life Science Products And Technologies
- The Role of Pricing and Reimbursement in Life Science Dealmaking
- Preparing for and Planning Deals for Maximum Strategic Impact
- Developing And Protecting The Product’s Intellectual Property Status
- Licensing Process
Highlights for Upcoming Week’s Life Science Events
- BioCentury This Week, See new program Webcast Starting Sunday, May 11, 2014, http://www.biocenturytv.com, Available anytime starting at 9:00 a.m. EDT; Topic: “What Does It Mean To Be Human?” Speaker: Dr. Pääbo of the Max Planck Institute for Evolutionary Anthropology
- Bio2Device Group, Tuesday Evening, May 13, 2014; Topic: “The Global Tilt and Why You Must Rethink the Future of Medical Technology;” Speaker: Thomas Loarie, CEO, Mercator MedSystems Inc.
- BioPharm PM, Tuesday, Wednesday and Thursday, May 13-15, 2014; Conference Topic: “The Diversity of PM roles in the BioPharmaceutical Industry: Implications and Opportunities”
- N CA ACRP, Thursday Evening, May 15, 2014; Topic: “Evolution or Revolution? What Transformative Efforts are Underway and Their Impact on the Clinical Research Enterprise;” Speaker: Terri Hinkley RN, BScN, MBA, CCRC, ACRP Deputy Executive Director
- Stanford Law Conference, Friday, May 16, 2014; Event: “IP Law and the Biosciences Conference”
- CACO-PBSS Luncheon, Friday Mid Day, May 16, 2014; Topic: “3-D printing in the creation of functional human tissues: advances and potential applications in medical research, drug discovery, preclinical drug evaluation and the future of patient care”
- RAPS and ASQ, Friday, May 16, 2014; Topic: “Evolving Standards and Gotchas: Human Factors, UDI and RoHS/REACH;” Speakers: Paul Arhanic, director, PricewaterhouseCoopers LLP ; Geoffrey Bock, senior business development manager, environmental services, TÜV Rheinland ; Michael Wiklund, PE, CHFP, founder and president, Wiklund Research & Design
Find all the details for this coming week’s upcoming events plus those through June 2014 in Audrey’s Picks. You can download the pdf of Audreys picks May 11, 2014 and Jobs That Crossed My Desk Through May 12, 2014 by right clicking on the highlighted titles.
You can always find my weekly blog and listings at http://audreysnetwork.wordpress.com/